Can a shot tame peanut allergies? small study tests xolair
NCT ID NCT00382148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested the drug Xolair (omalizumab) in 11 people with peanut allergies who had already completed a previous trial. The goal was to see if the drug could reduce serious allergic reactions. Participants received regular injections of Xolair and reported any peanut exposures. The study was small and open-label, meaning everyone knew they were getting the drug, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- omalizumab (Xolair)
- What this could lead to
- If it works, this could point toward a treatment that helps people with peanut allergies tolerate accidental exposure.
- What could go wrong
- This is a very small, early-phase study with only 11 people, so results may not apply to everyone. The drug also requires ongoing injections and is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peanut allergy cure in sight? trial tests tolerance in teens
- Can allergy drugs help kids tolerate peanut and more?
- Peanut allergy patch enters human safety trials
- Could supermarket peanuts and milk cure food allergies? new study investigates.
- New daily oral treatment aims to tame peanut allergy
- Poop pills could help peanut allergy sufferers